Trial Profile
Phase II clinical study of CIM331 in hemodialysis patients with pruritus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Nemolizumab (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 11 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2016 New trial record